GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
全球医疗保健公司GSK plc (LSE/NYSE: GSK)今天宣布了正在进行的临床试验的初步数据,这些数据表明其呼吸道合胞病毒(RSV)疫苗Arexvy可能对更广泛的成年人群有效。 目前,Arexvy已在50多个国家获准用于60岁及以上人群,在美国和欧洲获准用于50-59岁高风险人群。新数据可能将RSV保护范围扩大到18-49岁有基础疾病的成年人和免疫功能低下的成年人。 III期临床试验(NC ...
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...